49) Gebhardt, L., Abel, M., Zhou, J., Vogt, A.M., Shin, B.H., Herrick-Wagman, S.L., Santos, A., Puginier, J., Wurm, F.M., Wurm, M.,J., Yan, G.G., Adeniyi, A., Lim, K.H.S., Somers, W., Lin, L., D'Antona, AM, and Zhong, X* (2025). A robust high-titer, semi-automated, and in-culture antibody-capturing transient CHO platform technology. Antibodies 14(4):87. (*Corresponding author).
48) Scarcelli, J.J., Beal, K., Hartsourgh, R., Schenk, J., Cote, K., Ross, J., Quan, N., Sitaram, A., and Zhong, X* (2025). Expression of GNE mutant proteins increases CHO intracellular CMP-Neu5Ac levels without impact on bioprocess performance. Bioprocess Biosyst Eng. 48(8):1339-1347. (*Corresponding author).
47) Zhong, X*, D'Antona, AM, and Rouse, J.C. (2024). Mechanistic and therapeutic implication of protein and lipid sialylation in human diseases. Int J Mol Sci 25(22):11962. (*Corresponding author).
46) Zhong, X*, Yan, G.G., Chaturvedi, A., Li, X. Gao, Y., Girgenrath, M., Corcoran, C.J., Diblasio-Smith, L. LaVallie, E.R., de Rham, T., Zhou, J., Abel, M., Riegel, L., Lim, K.H.S., Bloom, L., Lin, L., and D'Antona, AM, (2024). Metabolic engineering of glycofusion bispecific antibodies for α-Dystroglycanopathies. Antibodies 13(4):83. (*Corresponding author).
45) D'Antona, AM, Lee, J., Zhang, M., Friedman, C., He, T., Mosyak, L., Lin, L., Silverman, M., Cameta, F., Meade, C., Hagman, T., Sousa, E., Cohen, J., Marquette, K., Ferguson, D., and Zhong, X* (2024). Tyrosine sulfation at antibody CDRL1 increase binding affinity and neutralization to interleukin-4. Int J Mol Sci 25(3):1931. (*Corresponding author).
44) Dimitrov, J., Mwangi, W., and Zhong, X.* (2023) Mechanism and strategies of unconventional antibody diversification for greater immune adaptability. Front Immunol.2023 14:1267556.. (*Corresponding author).
43) Zhou, J. Yan, G., Cluckey, D., Meade, C., Sorm, R., Tam, A., Ruth, M., Lim, S., Petridis, C., Lin, L., D'Antona, AM, and Zhong, X* (2023). Exploring parametric and mechanistic difference between Expi293FTM and ExpCHO-STM for transient antibody optimization. Antibodies 2023, 12(3), 53. (*Corresponding author).
42) Zhong, X*, D’ Antona, AM, and Dutta, K.. (2022) A surprising benefit of cysteine capping for antibody drug conjugates. J Cancer Immunol, 2022, Volume 4, Issue 2, p65-70 | DOI: 10.33696/cancerimmunol.4.068 (*Corresponding author).
41) Zhong, X*, D’ Antona, AM. (2022) A potential antibody repertoire diversification mechanism through tyrosine sulfation for biotherapeutics engineering and production. Front Immunol.2022. 13:1072702. (*Corresponding author).
40) Zhong, X*, Schenk J, Sakorafas P, Chamberland J, Tam A, Thomas LM, Yan G, D' Antona AM, Lin L, Nocula-Lugowska M, Zhang Y, Sousa E, Cohen J, Gu L, Abel M, Donahue J, Lim S, Meade C, Zhou J, Riegel L, Birch A, Fennell BJ, Franklin E, Gomes JM, Tzvetkova B, Scarcelli JJ..(2022) Impacts of fast production of afucosylated antibodies and Fc mutants in ExpiCHO-STM for enhancing FcRγIIIa binding and NK cell activation. J. Biotechnol 2022 360:79-91. (*Corresponding author).
39) Procopio-Melino, R., Kotch, F.W., Prashad, A.S., Gomes, J.M., Wang, W., Arve, B., Dwdy, A. Chen, L., Sperry, J., Hosselet, C., He, T., Kriz, R., Lin, L., Marquette, K., Tchistiakova, L. Somers, W., Rouse, J.C., and Zhong, X.* (2022) Cysteine metabolic engineering and selective disulfide reduction produce superior antibody-drug-conjugates. Sci. Rep2022. 12(1):7262. (*Corresponding author).
38) Zhong, X*, D’ Antona, AM, Scarcelli, J. and Rouse, J.. (2022) New opportunities in glycan engineering for therapeutic proteins. Antibodies.2022. 11(1):5. (*Corresponding author).
37) Zhong, X*, Schwab, A, Ma, W, Meade, CL, Zhou, J, D’ Antona, AM, Somers, W, and Lin, L. (2022) Large scale transient production in ExpiCHO-STM with enhanced N‐galactosylation-sialylation and PEI-based transfection. Methods Mol Biol. 2022.2323:142-150. (*Corresponding author)
36) Zhong, X*. and D’Antona, M. A. ( 2021) Recent advances in the molecular design and applications of multispecific biotherapeutics. Antibodies 10, 13. (*Corresponding author)
35) Apgar, JR, Tam, AS, Sorm, R, Moesta, S, King, AC, Yang, H, Kelleher, K, Murphy, D, D’Antona, AM, Yan, G, Zhong, X, Rodriguez, R, Ma, W, Ferguson, DE, Carven, GJ, Bennett, EM, and Lin, L. (2020) Modeling and mitigation of high-concentration antibody viscosity through structure based computational protein design. PLOS One 15(5):e0232713.
34) Zhong, X*, Jagarlapudi, S, Weng, Y, Ly, M., Rouse, JC, McClure, K, Ishino, T, Zhang, Y., Sousa, E, Cohen, J, Tzvetkova, B, Cote, K, Scarcelli, JJ, Johnson, K, Yaddanapudi, S, Villalobos, RG, Palandra, J, Opsahl, A, Lam, K, Yao, Q, Duan, W, Sievers, A, Zhou, J, Ferguson, D, D’ Antona, AM, Zollner, R, Zhu, HL, Kriz, R, Lin, L, Apgar, J, and Clerin, V. (2020). Structure-function relationships of the soluble form of the anti-ageing protein Klotho have therapeutic implications for managing kidney disease. J. Biol. Chem. 295(10):3115-3133. (*Corresponding author)
33) Zhong, X*, Ma, W, Meade, CL, Tam, AS, Llewellyn, E, Cornell, R, Cote, K, Scarcelli, JJ, Marshall, JK,
Tzvetkova, B, Figueroa, B, DiNino, D, Sievers, A, Lee, C, Guo, J, Mahan, E, Francis, C, Lam, K, D’ Antona, AM, Zollner, R, Zhu, HL, Kriz, R, Somers, W, and Lin, L. Transient CHO expression platform for robust antibody production and its enhanced N‐glycan sialylation on therapeutic glycoproteins. 2019. Biotechnol. Prog. 35:1-12. (*Corresponding author)
32) Ma, W, Pittman, DD, Stahl, M, Kriz, R, D'Antona, AM, and Zhong, X*. Involvement of Furin and Proprotein Convertase-5/6 in Proteolytic Processing of Factor VIII Albumin Fusion Protein. 2018. Res Trends Hematol Oncol: RTHO-102. DOI: 10.29011/RTHO-102/100002. (*Corresponding author)
31) Ferguson, DE, Mahan, ER, Ma, W, Bitzas, G., Zhong, X. Zollner, R., and D’Antona, AM. Parallel loading and complete automation of a 3-step mAb purification process for multiple samples using a customized preparative chromatography instrument with networked pumps. 2018. J. Chromatogr A. 1542:50-60.
30) Zhong, X*, He, T, Prashad, AS, Wang, W, Cohen, J, Ferguson, D, Tam, AS, Sousa, E, Lin, L, Tchistiakova, L, Gatto, S, D’Antona, A, Luan, YT, Ma, W, Zollner, R, Zhou, J, Arve, B, Somers, W, Kriz, R. Mechanistic understanding of the cysteine capping modifications of antibodies enables selective chemical engineering in live mammalian cells. 2017. J. Biotechnol. 248:48-58. (*Corresponding author).
29) Kulkami C, Finley JE, Bessire, AJ, Zhong, X, Musto, S, Graziani, EI. Development of Fluorophore-labeled thailanstatin antibody-drug conjugates for cellular trafficking studies. 2017. Bioconjug. Chem. 28(4):1041-1047.
28) Vugmeyster, Y., Zhang, YE, Zhong, X, Wright, J., Leung, SS. Pharmacokinetics of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions in mice. 2014. Int Immunopharmacol. 18(2):225-7.
27) Fennell, BJ, McDonnell, B, Tam, AS, Chang, L, Steven, J, Broadbent, ID, Gao, H, Kieras, E, alley, J, Luxenberg, D, Edmonds, J, Fitz, LJ, Miao, W, Whitters, MJ, Medley, QG, Guo, YJ, Darmanin-Sheehan, A, Autin, B, Shuilleabhain, DN, Cummins, E, King, A, Krebs, MR, Grace, C, Hickling, TP, Boisvert, A, Zhong, X, McKenna, M, Francis, C, Olland, S, Bloom, L, Paulsen, J, Somers, W., Jensen, A, Lin, L, Finlay, WJ, and Cunningham, O. CDR-restricted Engineering of Native Human scFvs Creates Highly Stable and Soluble Bifunctional Antibodies for Subcutaneous Delivery.2013.mAbs.5(6):882-95.
26) Zhong, X*and Wright, J.F. Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications. 2013. Int J. Cell Biol. 2013:273086. doi:10.1155/2013/273086. (*Corresponding author).
25) Zhong, X*, Kieras, E., Sousa, E., D’Antona, A., Baber, J.C., He, T., Desharnais, J., Wood, L., Luxenberg, D., Stahl, M., Kriz, R., Lin, L., Somers, W., Fitz, L.J., and Wright, J.F. Pyroglutamate and O-linked Glycan Determine Functional Production of Anti-IL17A and Anti-IL22 Peptide-Antibody Bispecific Genetic Fusions. 2013. J. Biol. Chem. 288:1409-1419. (*Corresponding author).
24) Zhong, X*, Cooley, C., Seth, N., Juo, Z.S., Presman, E., Resendes, N., Kumar, R., Allen, M., Mosyak, L., Stahl, M., Somers, W., and Kriz, R. Engineering Novel Lec1 Glycosylation Mutants in CHO-DUKX Cells: Molecular Insights and Effector Modulation of N-Acetylglucosaminyltransferase I. 2012. Biotechnology & Bioengineering 109(7):1723-1734. (*Corresponding author).
23) Zhong, X.*, Somers, W. Recent Advances in Glycosylation Modifications in the Context of Therapeutic Glycoproteins. InTech. Ed. Eastwood Leung. Integrative Proteomics. 2012. Book Chapter 10. ISBN:978-953-51-0070-6, Page 183-196 (*Corresponding author).
22) Zhong, X.*, Lu, Z., Zollner, R., Zhang, J., Kalayan, N., Braunstein, N., and Sidhu, M. Developing stable cell lines for the production of vaccine antigens. John Wiley and Sons. Ed. Singh & Srivastava. Development of Vaccines: From Discovery to Clinical Testing. 2011. Book Chapter 9. (*Corresponding author).
21) Zhong, X.*, Neumann, P., Corbo, M., and Loh, E. Recent Advances in Biotherapeutics Drug Discovery and Development. InTech. Ed. Izet M. Kapetanovic. Drug Discovery and Development-Present and Future. 2011. Book Chapter 15. Page 363-378. ISBN: 978-953-307-615-7. (*Corresponding author).
20) Kelly MP, Logue SF, Brennan J, Day J, Lakkaraju S, Jiang L, Zhong X, Tam M, Sukoff Rizzo S, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino M, Grauer S, Navarra RL, Kelley C, Comery TA, Murrills RJ, Houslay MD, Brandon NJ. Phosphodiesterase 11A (PDE11A) in brain is enriched in ventral hippocampus and deletion results in psychiatric disease-related phenotypes. 2010. Proc. Natl. Acad. Sci.U S A. 107:8457-62.
19) Zhong, X.* Paying for a long-fighting war: the health-care dilemma of cancer medicines. 2010.
Pharm. Med. 24(2):1-6. (*Corresponding author)
18) Zhong, X.*, Pocas, J., Liu, Y., Wu, P., Mosyak, L., Somers, W., and Kriz, R. Swift Residue-Screening Identifies Key N-Glycosylated Asparagines Sufficient for Surface Expression of Neuroglycoprotein Lingo-1. 2009. FEBS Letter. 583: 1034-8. (*Corresponding author)
17) Zhong, X#., Zhang, Y.#, Gjorka, Z., Li, Y., Stochaj, W., Celeste, A., Erbe, D.V., Kriz, R., Stahl, M., Tobin, J.F and Suri, V. H6PDH Interacts Directly with 1 1 beta-HSD1: Implications for Determining the Directionality of Glucocorticoid Catalysis. 2009. Arch. Biochem. Biophy. 483:45-54.
16) Zhong, X.*, Buddha, M. Guidotti, G. Kriz, R., Somers, W., Mosyak, L. Expression, purification, and crystallization of the ecto-enzymatic domain of rat E-NTDPase1 CD39. 2008. Acta Crystal. 16:1063-5. (*Corresponding author)
15) Zhong, X.*, Thamara, D., Lin, L., Bodine, P., Bhat, R., Presman, E., Pocas, J., Stahl, M., and Kriz, R. Regulation of secreted frizzled related protein-1 by heparin. 2007. J. Biol. Chem. 282:20523-20533. (*Corresponding author)
14) Zhong, X.* and Moseley, G. Mission Possible: Managing Innovation in Drug Discovery. 2007. Nature Biotechnology 25(8):945-946. (*Corresponding author)
13) Lu, Z., Laken, H., Zhang, J., Zhong, X., and Zollner, R. Generation of stable CHO cell lines for protein expression. 2007. Scion Publishing Limited. Ed. Dyson & Durocher, Expression Systems. Chapter 11: 183-201.
12) Mosyak, L., Georgiadis, K., Shane, T. Svenson, K., Hebert, T., McDonagh, T., Mackie, S., Olland, S., Lin, L., Zhong, X., Kriz, R., Reifenberg, E., Racie, L., Corcoran, C., Freeman, B., Zollner, R., Marvell, T., Vera, M., Sum, P., Lavallie, E., Stahl, M., and Somers, W. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. 2008. Protein Science 17:16-21.
11) Mosyak, L., Wood, A., Dwyer, B., Buddha, M., Johnson, M., Aulabaugh, A., Zhong, X., Presman, P., Benard, S., Kelleher, K., Wilhelm, J., Stahl. M. Kriz, R., Gao, Y., Cao, Z., Ling, H., Panglos, M., Walsh, F., and Somers, W. The structure of the lingo-1 ectodomain, a module implication in CNS repair inhibition. 2006. J. Biol. Chem. 281: 36378-36390.
10) Zhong, X.*, Malhotra, R., and Guidotti, G. A eukaryotic carboxyl-terminal signal sequence translocating large hydrophilic domains across membranes. 2005. FEBS Let. 579:5643-5650. (*Corresponding author).
9) Zhong, X*., Kriz, R., Kumar, R, and Guidotti, G. Distinctive roles of endoplasmic reticulum and Golgi glycosylation in functional surface expression of mammalian E-NTPDase1, CD39. 2005. Biochim. Biophy. Acta. 1723:143-150. (*Corresponding author)
8) Zhong, X., Kriz, R., Seehra, J., and Kumar, R. N-linked glycosylation of ADP receptor P2Y12 is essential for signal transduction but not for ligand binding and surface expression. 2004. FEBS Let. 562:111-117.
7) Zhong, X. Malhotra, R, and Guidotti, G. ATP uptake in Golgi and extracellular release require Mcd4 protein and vacuolar H+-ATPase. 2003. J. Biol. Chem. 278:33436-33444
6) Zhong, X. Malhotra, R., Woodruff, R., and Guidotti, G. Mammalian plasma membrane ecto-ATPase CD39 is not active intracellularly: N-glycosylation state of CD39 correlates with surface activity and localization. 2001. J. Biol. Chem. 276:41518-41525.
5) Zhong, X. Malhotra, R, and Guidotti, G. Regulation of yeast ectoapyrase Ynd1p activity by activator subunit Vma13p of vacuolar H+-ATPase. 2000. J. Biol. Chem.275:35592-35599.
4) Zhong, X. and Guidotti, G. A yeast Golgi E-type ATPase with an unusual membrane topology. 1999. J. Biol. Chem. 274:32704-32711.
3) Zhong, X. and Tai, P.C. When an ATPase is not an ATPase: At low temperatures the C-terminal domain of the ABC transporter CvaB is a GTPase. 1998. J. Bacteriol. 180: 1347-1353.
2) Hwang, J., Zhong, X., and Tai, P. C. Interactions of dedicated export membrane proteins: CvaA, a member of the membrane fusion protein family, interacts with CvaB and TolC to form colicin V secretion complex. 1997. J.Bacteriol. 179: 6264 - 6270.
1) Zhong, X., Kolter, R., and Tai, P.C. Processing of Colicin V-1, a secretable marker protein of a bacterial ATP binding cassette export system, requires membrane integrity, energy, and cytosolic factors. 1996. J. Biol. Chem. 271: 28057-28063.